ONESOURCE Specialty Pharma Signs Strategic Manufacturing Deal With Formycon AG For 5 Global Biosimilars
ONESOURCE Specialty Pharma partners with Formycon AG for global biosimilar manufacturing, boosting its CDMO order book and validating its large-scale biologics infrastructure.
Read the full articleYou might also wanna read
OneSource Specialty Pharma ties up with Germany’s Formycon for Biosimilar manufacturing
Under the agreement, OneSource will provide integrated Drug Substance and Drug Product manufacturing for Formycon’s biosimilar programs from
Europe–US new drug manufacturing outsourcing gap widens, reveals GlobalData
Contract manufacturing facilities located in the US and Europe provide biopharma companies with strategic options to diversify supply chains
Biosimilars new trend after generics: Track these stocks for the next big story in pharma
The Indian pharma industry is now placing a major bet on biosimilars, which is hotting up after generics. With the expiration of patents on
GC Biopharma, Cytiva Deepen Supply Chain Ties for Alyglo Ingredients
GC Biopharma and Cytiva signed an MOU to build a priority supply system for Alyglo's core consumables and expand cooperation on mRNA and cel
Celltrion's High-Margin Follow-On Products Expand Share in Europe
Celltrion's high-margin follow-on biosimilars are expanding their share across Europe, with Omlyclo reaching 16% and Vegzelma and Yuflyma ho
Celltrion Poised for Profitability Leap on New Biosimilars
Celltrion is poised for a profitability leap as new biosimilars like Remsima SC and Omlyclo boost its product mix, with Q2 operating profit
Comments
Sign in to join the conversation.
No comments yet. Be the first.